Skip to content

Released May 6, 2014, after the close

10-Q filed May 6, 2014, 36 days after period end · 0001390478-14-000024

Q1 2014 · 10-Q
Revenue$2.17M−21.0% vs Q1 2013+51.3% vs Q4 2013
Net Income-$2.54MN/M vs Q1 2013N/M vs Q4 2013
EPS Diluted-$0.02N/M vs Q1 2013no prior Q4 2013 on file
Operating Income-$11,849,000N/M
Operating Cash Flow-$8,048,000N/M
Free Cash Flowderived-$8,070,000—
Margins · derived
Operating margin-545.3%−304.9 pt vs Q1 2013
Net margin-116.7%+483.0 pt vs Q1 2013

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2014Q1 2013Q1 2012Q1 2011
Revenue$2.17M$2.75M$2.75M—
Net Income-$2.54M-$16.49M-$10.54M-$3.84M
EPS Diluted-$0.02-$0.11-$0.52-$0.19

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR